

MARYLAND Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	6,208,400	6,497,600	6,762,700	7,022,300
Prediabetes	1,737,000	1,877,900	2,013,000	2,093,000
Diagnosed diabetes	502,700	623,100	729,200	817,500
Undiagnosed diabetes	185,900	218,900	243,100	258,200
Total with diabetes (diagnosed and undiagnosed)	688,600	842,100	972,200	1,075,700
Complications:				
Visual impairment	82,400	99,200	112,700	122,600
Renal failure	1,200	1,430	1,620	1,750
Leg amputations	1,040	1,180	1,280	1,320
Annual deaths attributable to diabetes	5,410	6,410	7,120	7,560
Total annual cost (2015 dollars)	\$7.9 B	\$9.6 B	\$11.1 B	\$12.3 B
Annual medical costs	\$5.6 B	\$6.7 B	\$7.8 B	\$8.6 B
Annual nonmedical costs	\$2.3 B	\$2.9 B	\$3.3 B	\$3.7 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	837,100	962,200	1,104,800	1,235,700
Prediabetes	426,900	490,700	563,400	630,200
Diagnosed diabetes	158,200	181,800	208,800	233,500
Undiagnosed diabetes	58,600	67,400	77,300	86,500
Total with diabetes (diagnosed and undiagnosed)	216,800	249,200	286,100	320,000
Complications:				
Visual impairment	29,600	33,100	37,100	40,400
Renal failure	490	540	600	650
Leg amputations	370	390	410	430
Annual deaths attributable to diabetes	3,740	4,290	4,630	4,760
Total annual cost (2015 dollars)	\$2.8 B	\$3.2 B	\$3.7 B	\$4.1 B
Annual medical costs	\$2.6 B	\$3.0 B	\$3.4 B	\$3.8 B
Annual nonmedical costs	\$0.2 B	\$0.2 B	\$0.3 B	\$0.3 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.